摘要
罗氟司特(roflumilast,1)化学名为N-(3,5-二氯吡啶4-基)-3-环丙甲氧基4-二氟甲氧基苯甲酰胺,是由德国安达(Altana)公司研发,瑞士奈科明公司(Nycomed Pharma GmbH)完成Ⅲ期临床试验的磷酸二酯酶4(PDFA)抑制剂,于2010年7月在欧洲获得批准,随后在德国、英国和西班牙上市,商品名为Daxas。2011年3月又获得美国FDA批准,在美国上市。
出处
《中国药物化学杂志》
CAS
CSCD
2013年第6期506-509,共4页
Chinese Journal of Medicinal Chemistry
参考文献16
-
1钟永刚,陈国华,李昂,李素义.罗氟司特的合成[J].中国医药工业杂志,2011,42(12):884-886. 被引量:12
-
2AMARI G, ARMANI E, GHIDINI E. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodi- esterase inhibitors : WO, 2008006509 [P]. 2008 - 01 -17. 被引量:1
-
3LOHRAY B B,LOHRAY V B, DAVE M G. Prepa- ration of roflumilast and its analogs: IN, 2004MU00478 [ P]. 2007 - 10 - 12. 被引量:1
-
4GAVHANE S B, WAKADE S M, KADAM S M. Novel process for the preparation of 3-( cyclopropyl- methoxy ) -N-( 3, 5-dichloropyridin-4-yl ) -4-( diflu- oromethoxy) benzamide: WO, 2012147098 [ P ]. 2012-11 -01. 被引量:1
-
5王一茜,戚太林,刘威加.一种罗氟斯特原料及中间体的制备方法:中国,102532011[P].2012-01-05. 被引量:1
-
6WILLIAMS E L, WU T C. Process for production of fluoroalkoxy-substituted benzamides and their inter- mediates: WO,2004033430 [ P ]. 2004 - 04 - 22. 被引量:1
-
7廖明毅,李瑞,杨少宁,等.3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成新方法:中国,102093194[P].2011-06-15. 被引量:1
-
8严洁,黄欣.高生物利用度的罗氟司特化合物:中国.102351787[P].2012-02-15. 被引量:1
-
9BOSE P, SACHDEVA Y P, RATHORE R S, et al. Process foe the preparation of roflumilast: WO, 2005026095 [ P ]. 2005 - 03 - 24. 被引量:1
-
10丁克,朱克明,肖广常.一种制备罗氟司特的方法:中国,102336704[P].2012-02一01. 被引量:1
二级参考文献10
-
1Bose P, Sachdeva YP, Rathore RS, et al. Process for the preparation of roflumilast: WO, 2005 026095 [P-. 2005-03-24. (CA 2005, 142: 336129). 被引量:1
-
2Palle VP, Balachandran S, Salman M, et al. lnhibitors ofphosphodiesterasetype-lV: WO, 2005021515 [P]. 2005-03-10. (CA 2005, 142: 298095). 被引量:1
-
3Gharat LA, Gajera JM, Patil SD, et al. Novel processes for preparing 6- (difluoromethoxy) [ 1 ] benzofuro [3,2- c] pyridine-9-carboxaldehyde, a novel intermediate for the systhesis of PDE IV inhibitors: WO, 2008142542 [P]. 2008-11-27. (CA2008, 150: 5710). 被引量:1
-
4Amari G, Armani E, Villetti G. Ester derivatives as phosphodiesterase inhibitors: WO, 2009077068 [P]. 2009-06-25. (CA 2009, 151: 77927). 被引量:1
-
5Amari G, Armani E, Ghidini E. Derivatives of 1-phenyl-2- pyridinyl alkylene alcohols as phosphodiesterase inhibitors: WO, 2008006509 [P]. 2008-01-17. (CA 2008, 148: 168589). 被引量:1
-
6Kelly DJ, Williams S J, Zammit S. Halogenated analogues of anti-fibrotic agents and their preparation: WO, 2009079692 [P]. 2009-07-02. (CA2009, 151: 100915). 被引量:1
-
7Amschler H, Flockerzi D, Gutterer B, et al. Fluoroalkoxysubstituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors: WO, 9501338 [P]. 1995-01-12. (CA 1995, 122: 239550). 被引量:1
-
8Duplantier A J, Eggler JF, Marfat A, et al. Catechol diethers as selective PDEIV inhibitors: WO, 9412461 [P]. 1994-06-09. (CA 1994, 121: 255405). 被引量:1
-
9冯桂山,宋宁,段争,吴雅莉.罗氟司特治疗慢性阻塞性肺疾病药理作用的临床前研究现况[J].临床荟萃,2011,26(4):363-366. 被引量:20
-
10冯波.第二代PDE4抑制剂Roflumilast[J].药学进展,2002,26(2):121-122. 被引量:7
共引文献11
-
1杨展雄,孙焕亮,蔡开明.罗氟司特的合成路线图解[J].华西药学杂志,2014,29(2):222-223. 被引量:4
-
2沈卫阳,刘斐烨,费滢.HPLC法测定罗氟司特原料药的含量[J].海峡药学,2014,26(4):52-54. 被引量:1
-
3周海洋,董旭,翟海民,陈明强.罗氟司特中间体3-环丙基甲氧基-4-二氟甲氧基苯甲醛的合成[J].药学研究,2013,32(11):678-679. 被引量:2
-
4宋蕊,孙岩.HPLC法测定罗氟司特原料药的含量[J].科技致富向导,2015,0(2):94-94.
-
5梁兴运,高立国,穆帅,韩学文,范巧云,张晓军,王平保.罗氟司特中3,5-二氯-4-氨基吡啶引入两个杂质的合成研究[J].现代药物与临床,2015,30(5):483-486.
-
6蔡志强,马维英.罗氟司特的合成工艺改进[J].应用化工,2015,44(7):1366-1368. 被引量:1
-
7曹一帆,刘昭文,郭小华,杨凯.罗氟司特新合成工艺的研究[J].海峡药学,2016,28(3):231-232. 被引量:1
-
8汪令,赵经伟,贾爱琼,夏颖频,王冰冰.罗氟司特的合成[J].四川化工,2016,19(5):1-3. 被引量:2
-
9刘昭文,杨凯,郭小华,曾发挥.罗氟司特的合成研究[J].海峡药学,2018,30(10):87-88.
-
10张云,于梦,付丙月,段崇刚,孙玲.顶空气相色谱法测定罗氟司特中起始原料溴甲基环丙烷的残留量[J].海峡药学,2021,33(3):60-62. 被引量:1
同被引文献16
-
1BOLAND S,ALEN J,BOURIN A,et al.Novel Roflumilast analogs as soft PDE4 inhibitors[J].Bioorg Med Chem Lett,2014,24(18):4594. 被引量:1
-
2MILARA J,MORELL A,BALLESTER B,et al.Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist[J].Respir Res,2015, 16(1):12. 被引量:1
-
3HAN S,KARLOWICZ-BODALSKA K,POTACZEK P,et al. Identification of unknown impurity of azelaic acid in liposomal formulation assessed by HPLC-ELSD,GC-FID,and GC-MS[J]. AAPS Pharm Sci Tech,2014,15(1):111. 被引量:1
-
4JIN C,YAN C,LUO Y,et al.Fast and direct quantification of underivatized muscone by ultra performance liquid chromatography coupled with evaporative light scattering detection[J].J Sep Sci, 2013,36(11):1762. 被引量:1
-
5BOBBALA S,MCDOWELL A,HOOK S.Quantitation of the immunological adjuvants,monophosphoryl lipid A and Quil A in poly(lactic-co-glycolic acid)nanoparticles using high performance liquid chromatography with evaporative light scattering detection[J].J Chromatogr B,2015,975:45. 被引量:1
-
6HAN S,KARLOWICZ-BODALSKA K,SZURA D,et al. Application of HPLC with ELSD detection for the assessment of azelaic acid impurities in liposomal formulation[J].Sci World J, 2013,2013. 被引量:1
-
7SHANMUGAVELAN P,KIM SY,KIM JB,et al.Evaluation of sugar content and composition in commonly consumed Korean vegetables,fruits,cereals,seed plants,and leaves by HPLC-ELSD[J].Carbohydr Res,2013,380:112. 被引量:1
-
8SIMAL-Gá N DA R A J,SARRIA-VIDAL M,RIJK R. Determination of paraffins in food simulants and packaging materials by liquid chromatography with evaporative mass detection and identification of paraffin type by liquid chromatography/gas chromatography and Fourier transform infrared spectroscopy[J].J AOAC Int,2000,83(2):311. 被引量:1
-
9ALSAADI MM,CARTER KC,MULLEN AB.High performance liquid chromatography with evaporative light scattering detection for the characterisation of a vesicular delivery system during stability studies[J].J Chromatogr A,2013,1320:80. 被引量:1
-
10DVO?á?KOVáE,?NóBLOVáM,HRDLI?KA P.Carbohydrate analysis:From sample preparation to HPLC on different stationary phases coupled with evaporative light-scattering detection[J].J Sep Sci,2014,37(4):323. 被引量:1
-
1金伟秋.roflumilast首次申请上市[J].国外药讯,2004(4):20-20.
-
2高颖昌.奥安达[J].天坛药讯,2004,16(2):4-4.
-
3汤慧芳,陈季强,王鹏.磷酸二酯酶4作为抗炎药物靶点的研究现状及未来发展方向[J].中国药科大学学报,2006,37(1):9-13. 被引量:9
-
4吴冠青,李玉升.帝安达胶囊镇痛效果的Ⅱ,Ⅲ期临床[J].中国新药杂志,1993,2(4):37-39.
-
5钟永刚,陈国华,李昂,李素义.罗氟司特的合成[J].中国医药工业杂志,2011,42(12):884-886. 被引量:12
-
6韩青洁,李金玲,李琼.注射用泮托拉唑钠与依达拉奉注射液存在配伍禁忌[J].西南国防医药,2015,25(5):574-574. 被引量:4
-
7梁兴运,高立国,穆帅,韩学文,范巧云,张晓军,王平保.罗氟司特中3,5-二氯-4-氨基吡啶引入两个杂质的合成研究[J].现代药物与临床,2015,30(5):483-486.
-
8罗娟(摘).呼吸系统、特殊感官及皮肤用药——Pfizer撤消对Daxas的支持[J].国外药讯,2006(1):20-21.
-
9俞小弟,楼少杰,金文虎,罗晓燕,许煦,冀亚飞.泮托拉唑钠的合成工艺改进[J].合成化学,2007,15(6):792-794. 被引量:1
-
10通用名药与药物经济学[J].国外药讯,2007(11):44-46.